267 related articles for article (PubMed ID: 30803073)
21. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.
Patel MM; Patel BM
CNS Drugs; 2017 Feb; 31(2):109-133. PubMed ID: 28101766
[TBL] [Abstract][Full Text] [Related]
22. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles and blood-brain barrier: the key to central nervous system diseases.
Domínguez A; Suárez-Merino B; Goñi-de-Cerio F
J Nanosci Nanotechnol; 2014 Jan; 14(1):766-79. PubMed ID: 24730296
[TBL] [Abstract][Full Text] [Related]
24. Current approaches to enhance CNS delivery of drugs across the brain barriers.
Lu CT; Zhao YZ; Wong HL; Cai J; Peng L; Tian XQ
Int J Nanomedicine; 2014; 9():2241-57. PubMed ID: 24872687
[TBL] [Abstract][Full Text] [Related]
25. Targeting specific cells in the brain with nanomedicines for CNS therapies.
Zhang F; Lin YA; Kannan S; Kannan RM
J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
[TBL] [Abstract][Full Text] [Related]
26. Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood-Brain Barrier Both in Vitro and in Vivo.
Aparicio-Blanco J; Romero IA; Male DK; Slowing K; García-García L; Torres-Suárez AI
Mol Pharm; 2019 May; 16(5):1999-2010. PubMed ID: 30865462
[TBL] [Abstract][Full Text] [Related]
27. siRNA Therapeutics for Protein Misfolding Diseases of the Central Nervous System.
Zabel MD; Mollnow L; Bender H
Methods Mol Biol; 2021; 2282():377-394. PubMed ID: 33928585
[TBL] [Abstract][Full Text] [Related]
28. Differential receptor-mediated drug targeting to the diseased brain.
Rip J; Schenk GJ; de Boer AG
Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
[TBL] [Abstract][Full Text] [Related]
29. Intracellular delivery of proteins by nanocarriers.
Ray M; Lee YW; Scaletti F; Yu R; Rotello VM
Nanomedicine (Lond); 2017 Apr; 12(8):941-952. PubMed ID: 28338410
[TBL] [Abstract][Full Text] [Related]
30. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
[TBL] [Abstract][Full Text] [Related]
31. Prodrug strategy for enhanced therapy of central nervous system disease.
Xia X; Zhou Y; Gao H
Chem Commun (Camb); 2021 Sep; 57(71):8842-8855. PubMed ID: 34486590
[TBL] [Abstract][Full Text] [Related]
32. Nanomedicines for the Treatment of CNS Diseases.
Reynolds JL; Mahato RI
J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
[TBL] [Abstract][Full Text] [Related]
33. A TfR-Binding Cystine-Dense Peptide Promotes Blood-Brain Barrier Penetration of Bioactive Molecules.
Crook ZR; Girard E; Sevilla GP; Merrill M; Friend D; Rupert PB; Pakiam F; Nguyen E; Yin C; Ruff RO; Hopping G; Strand AD; Finton KAK; Coxon M; Mhyre AJ; Strong RK; Olson JM
J Mol Biol; 2020 Jun; 432(14):3989-4009. PubMed ID: 32304700
[TBL] [Abstract][Full Text] [Related]
34. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
35. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
36. Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies.
Smith MW; Gumbleton M
J Drug Target; 2006 May; 14(4):191-214. PubMed ID: 16777679
[TBL] [Abstract][Full Text] [Related]
37. Overcoming the Blood-Brain Barrier for Gene Therapy via Systemic Administration of GSH-Responsive Silica Nanocapsules.
Wang Y; Wang X; Xie R; Burger JC; Tong Y; Gong S
Adv Mater; 2023 Feb; 35(6):e2208018. PubMed ID: 36445243
[TBL] [Abstract][Full Text] [Related]
38. Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review.
Zhang Y; Guo P; Ma Z; Lu P; Kebebe D; Liu Z
J Nanobiotechnology; 2021 Aug; 19(1):255. PubMed ID: 34425832
[TBL] [Abstract][Full Text] [Related]
39. Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.
Calias P; Banks WA; Begley D; Scarpa M; Dickson P
Pharmacol Ther; 2014 Nov; 144(2):114-22. PubMed ID: 24854599
[TBL] [Abstract][Full Text] [Related]
40. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
